Filters
In expectant mothers, a history of abdominal surgery for Crohn’s disease (CD) exerts no adverse effect on pregnancy, neonatal, or wound healing outcomes, according to the prospective PIANO study.
In women with faecal incontinence (FI), faecal consistency of Bristol Stool Chart (BSC) ≥5 results in significantly worse clinical severity and quality of life (QoL), reports a study.
In patients with upfront resectable pancreatic cancer, minimally invasive left pancreatectomy (MILP) and open left pancreatectomy (OLP) appear to result in similar oncological outcomes, as shown in the DIPLOMA trial.
The LIVE-SMART trial presented at AASLD 2025 shows that lactulose and Tai chi may prevent falls in individuals with cirrhosis and portal hypertension.
The post hoc subgroup analysis of the phase III MITIGATE trial shows the benefit of the humanized monoclonal anti-CD19 antibody inebilizumab in adults with IgG4-related disease (IgG4-RD) with pancreas, bile duct, and liver involvement at baseline.
Treatment with cilofexor in patients with noncirrhotic primary sclerosing cholangitis (PSC) does not appear to reduce the rate of fibrosis progression, according to a phase III study.
In patients with Crohn’s disease (CD), initiating treatment with vedolizumab early than late in the disease course may lead to better safety and efficacy outcomes, according to a phase IV open-label cohort study.
Supplementation with palmitoleic acid (POA) 500 or 1,000 mg/day does not appear to substantially reduce high-sensitivity C-reactive protein (hs-CRP) or change other biomarkers in adults relative to placebo, reports a study.
In the treatment of patients with hereditary haemorrhagic telangiectasia (HHT), use of the novel allosteric, selective AKT inhibitor engasertib appears to be safe and reduce the frequency and duration of epistaxis, according to a proof-of-concept study.
Patients with chronic hepatitis D virus (HDV) infection appear to respond to treatment with the combination of tobevibart plus elebsiran, according to the phase II, open-label SOLSTICE trial.
